Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2025)
Top diagnostic & research stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research

Zen Rating Price Value Growth Financials Momentum Sentiment Forecast Dividends Due Diligence

Diagnostics & Research is Zen Rated B and is the 47th ranked industry out of 145 stock market industries

Ticker	Company	Exchange	Industry	Market Cap	Price	1d %	EBITDA	P/E	D/E	Country
SHC	SOTERA HEALTH CO	NASDAQ	Diagnostics & Research	$4.78B	$16.84	-0.53%	$428.10M	84.20x	4.79	United States
IDXX	IDEXX LABORATORIES INC	NASDAQ	Diagnostics & Research	$57.97B	$725.93	-0.93%	$1.45B	57.07x	1.17	United States
DHR	DANAHER CORP	NYSE	Diagnostics & Research	$161.37B	$228.46	0.83%	$6.87B	46.82x	0.56	United States
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	NYSE	Diagnostics & Research	$9.09B	$184.67	5.67%	$513.77M	-121.49x	1.19	United States
ILMN	ILLUMINA INC	NASDAQ	Diagnostics & Research	$19.55B	$127.95	0.31%	$1.27B	28.62x	1.59	United States
QGEN	QIAGEN NV	NYSE	Diagnostics & Research	$10.19B	$46.82	-0.26%	$731.11M	25.17x	0.80	Netherlands
CDNA	CAREDX INC	NASDAQ	Diagnostics & Research	$969.51M	$18.85	8.08%	$70.49M	16.11x	0.39	United States
MEDP	MEDPACE HOLDINGS INC	NASDAQ	Diagnostics & Research	$16.24B	$576.49	-1.24%	$563.19M	39.32x	4.97	United States
TMO	THERMO FISHER SCIENTIFIC INC	NYSE	Diagnostics & Research	$218.08B	$580.45	0.01%	$11.28B	33.47x	1.02	United States
A	AGILENT TECHNOLOGIES INC	NYSE	Diagnostics & Research	$42.32B	$149.26	0.30%	$1.80B	34.87x	0.92	United States
FLGT	FULGENT GENETICS INC	NASDAQ	Diagnostics & Research	$880.38M	$28.48	0.28%	-$21.75M	-20.49x	0.08	United States
PRE	PRENETICS GLOBAL LTD	NASDAQ	Diagnostics & Research	$199.95M	$14.39	1.77%	N/A	-4.03x	0.22	Hong Kong
BNR	BURNING ROCK BIOTECH LTD	NASDAQ	Diagnostics & Research	$245.11M	$22.75	4.79%	N/A	-13.85x	0.48	China
CAI	CARIS LIFE SCIENCES INC	NASDAQ	Diagnostics & Research	$7.69B	$27.24	4.33%	N/A	N/A	1.06	United States
IQV	IQVIA HOLDINGS INC	NYSE	Diagnostics & Research	$38.63B	$227.24	0.71%	$3.43B	30.96x	3.64	United States
PRPO	PRECIPIO INC	NASDAQ	Diagnostics & Research	$44.50M	$25.40	3.42%	$490.00k	-30.60x	0.54	United States
FONR	FONAR CORP	NASDAQ	Diagnostics & Research	$95.23M	$14.46	0.49%	$14.14M	12.80x	0.33	United States
NEOG	NEOGEN CORP	NASDAQ	Diagnostics & Research	$1.29B	$5.94	0.34%	-$879.32M	-1.24x	0.59	United States
LH	LABCORP HOLDINGS INC	NYSE	Diagnostics & Research	$22.03B	$265.76	-0.06%	$2.21B	25.93x	1.10	United States
MTD	METTLER TOLEDO INTERNATIONAL INC	NYSE	Diagnostics & Research	$29.31B	$1,434.88	-0.85%	$1.23B	35.71x	-15.13	United States
DGX	QUEST DIAGNOSTICS INC	NYSE	Diagnostics & Research	$20.31B	$182.61	0.03%	$2.10B	21.14x	1.23	United States
MYGN	MYRIAD GENETICS INC	NASDAQ	Diagnostics & Research	$683.26M	$7.33	4.42%	-$353.20M	-1.69x	0.95	United States
WAT	WATERS CORP	NYSE	Diagnostics & Research	$23.67B	$397.62	-0.25%	$1.04B	36.45x	1.09	United States
BLLN	BILLIONTOONE INC	NASDAQ	Diagnostics & Research	N/A	$102.76	-10.58%	N/A	N/A	-0.57	United States
GRAL	GRAIL INC	NASDAQ	Diagnostics & Research	$3.94B	$101.19	3.91%	-$388.10M	-9.48x	0.16	United States
NEO	NEOGENOMICS INC	NASDAQ	Diagnostics & Research	$1.57B	$12.12	0.41%	-$32.65M	-13.77x	0.64	United States
ICLR	ICON PLC	NASDAQ	Diagnostics & Research	$14.34B	$187.78	2.53%	$1.21B	25.31x	0.77	Ireland
CSTL	CASTLE BIOSCIENCES INC	NASDAQ	Diagnostics & Research	$1.15B	$39.41	0.79%	$24.00M	-96.12x	0.21	United States
XGN	EXAGEN INC	NASDAQ	Diagnostics & Research	$164.99M	$7.28	2.54%	-$12.56M	-7.91x	2.46	United States
ACRS	ACLARIS THERAPEUTICS INC	NASDAQ	Diagnostics & Research	$301.20M	$2.78	2.96%	-$141.19M	-1.76x	0.46	United States
NOTV	INOTIV INC	NASDAQ	Diagnostics & Research	$32.29M	$0.94	8.05%	$5.65M	-0.29x	3.86	United States
MBAI	CHECK-CAP LTD	NASDAQ	Diagnostics & Research	$10.01M	$1.71	3.01%	-$25.79M	-0.40x	-1.26	Israel
GH	GUARDANT HEALTH INC	NASDAQ	Diagnostics & Research	$13.36B	$105.96	2.01%	-$354.11M	-33.01x	-4.60	United States
RVTY	REVVITY INC	NYSE	Diagnostics & Research	$11.71B	$103.26	0.52%	$775.92M	51.89x	0.65	United States
RDNT	RADNET INC	NASDAQ	Diagnostics & Research	$6.13B	$79.46	0.84%	$268.98M	-467.41x	2.22	United States
NTRA	NATERA INC	NASDAQ	Diagnostics & Research	$32.88B	$238.21	0.66%	-$249.43M	-104.02x	0.46	United States
TWST	TWIST BIOSCIENCE CORP	NASDAQ	Diagnostics & Research	$1.91B	$31.17	4.95%	-$52.12M	-23.98x	0.36	United States
BDSX	BIODESIX INC	NASDAQ	Diagnostics & Research	$64.76M	$8.14	3.96%	-$26.13M	-1.52x	-52.52	United States
MDXH	MDXHEALTH SA	NASDAQ	Diagnostics & Research	$17.57M	$3.55	2.31%	-$2.60M	-0.70x	-19.67	Belgium
DRIO	DARIOHEALTH CORP	NASDAQ	Diagnostics & Research	$80.20M	$11.85	-0.34%	-$36.24M	-1.06x	0.57	Israel
IMDX	INSIGHT MOLECULAR DIAGNOSTICS INC	NASDAQ	Diagnostics & Research	$153.07M	$5.34	-3.17%	-$58.47M	-1.67x	-5.78	United States
STIM	NEURONETICS INC	NASDAQ	Diagnostics & Research	$91.77M	$1.34	1.52%	-$33.50M	-1.61x	4.17	United States
OPK	OPKO HEALTH INC	NASDAQ	Diagnostics & Research	$1.05B	$1.37	3.01%	$45.18M	-5.71x	0.53	United States
PSNL	PERSONALIS INC	NASDAQ	Diagnostics & Research	$903.14M	$10.17	0.69%	-$62.03M	-12.25x	0.42	United States
NDRA	ENDRA LIFE SCIENCES INC	NASDAQ	Diagnostics & Research	$6.95M	$5.96	-0.55%	-$7.84M	0.31x	10.46	United States
LAB	STANDARD BIOTOOLS INC	NASDAQ	Diagnostics & Research	$553.77M	$1.44	1.41%	-$107.13M	-4.36x	0.35	United States
BIAF	BIOAFFINITY TECHNOLOGIES INC	NASDAQ	Diagnostics & Research	$7.06M	$1.57	9.79%	-$14.11M	-0.07x	0.30	United States
BNBX	BNB PLUS CORP	NASDAQ	Diagnostics & Research	$4.02M	$3.11	1.30%	-$12.85M	-0.01x	0.41	United States
TRIB	TRINITY BIOTECH PLC	NASDAQ	Diagnostics & Research	$17.96M	$1.00	-0.99%	-$19.87M	-0.56x	-3.94	Ireland
SERA	SERA PROGNOSTICS INC	NASDAQ	Diagnostics & Research	$119.26M	$3.09	6.55%	-$31.13M	-4.01x	0.32	United States
XWEL	XWELL INC	NASDAQ	Diagnostics & Research	$4.61M	$0.80	2.56%	-$13.29M	-0.24x	-2.90	United States
PRPH	PROPHASE LABS INC	NASDAQ	Diagnostics & Research	$6.23M	$0.14	-4.26%	-$18.11M	-0.08x	8.58	United States
ADVB	ADVANCED BIOMED INC	NASDAQ	Diagnostics & Research	$8.44M	$0.39	0.00%	-$3.09M	-2.44x	1.08	United States
VNRX	VOLITIONRX LTD	NYSEMKT	Diagnostics & Research	$34.88M	$0.28	-5.02%	-$21.14M	-1.23x	-1.22	United States
MYNZ	MAINZ BIOMED NV	NASDAQ	Diagnostics & Research	$4.75M	$1.16	0.00%	-$18.40M	-0.21x	2.89	Germany
EXAS	EXACT SCIENCES CORP	NASDAQ	Diagnostics & Research	$19.18B	$101.25	0.05%	-$710.69M	-18.93x	1.36	United States
ISPC	ISPECIMEN INC	NASDAQ	Diagnostics & Research	$4.46M	$0.46	9.88%	-$9.69M	-0.06x	1.93	United States

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Dec 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Sotera Health Co (NASDAQ:SHC)

Sotera Health Co (NASDAQ:SHC) is the #1 top diagnostic & research stock out of 57 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Sotera Health Co (NASDAQ:SHC) is: Value: C, Growth: A, Momentum: B, Sentiment: A, Safety: B, Financials: C, and AI: C.

Sotera Health Co (NASDAQ:SHC) has a Due Diligence Score of 24, which is -2 points lower than the diagnostic & research industry average of 26. Although this number is below the industry average, our proven quant model rates SHC as a "A".

SHC passed 8 out of 33 due diligence checks and has weak fundamentals. Sotera Health Co has seen its stock return 31.25% over the past year, overperforming other diagnostic & research stocks by 16 percentage points.

Sotera Health Co has an average 1 year price target of $18.00, an upside of 6.89% from Sotera Health Co's current stock price of $16.84.

Sotera Health Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Sotera Health Co, 25% have issued a Strong Buy rating, 25% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Idexx Laboratories (NASDAQ:IDXX)

Idexx Laboratories (NASDAQ:IDXX) is the #2 top diagnostic & research stock out of 57 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Idexx Laboratories (NASDAQ:IDXX) is: Value: C, Growth: C, Momentum: B, Sentiment: B, Safety: C, Financials: A, and AI: C.

Idexx Laboratories (NASDAQ:IDXX) has a Due Diligence Score of 50, which is 24 points higher than the diagnostic & research industry average of 26.

IDXX passed 17 out of 33 due diligence checks and has strong fundamentals. Idexx Laboratories has seen its stock return 68% over the past year, overperforming other diagnostic & research stocks by 53 percentage points.

Idexx Laboratories has an average 1 year price target of $737.14, an upside of 1.54% from Idexx Laboratories's current stock price of $725.93.

Idexx Laboratories stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Idexx Laboratories, 57.14% have issued a Strong Buy rating, 14.29% have issued a Buy, 28.57% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Danaher (NYSE:DHR)

Danaher (NYSE:DHR) is the #3 top diagnostic & research stock out of 57 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Danaher (NYSE:DHR) is: Value: C, Growth: C, Momentum: C, Sentiment: B, Safety: C, Financials: B, and AI: C.

Danaher (NYSE:DHR) has a Due Diligence Score of 32, which is 6 points higher than the diagnostic & research industry average of 26.

DHR passed 11 out of 38 due diligence checks and has average fundamentals. Danaher has seen its stock lose -5.15% over the past year, underperforming other diagnostic & research stocks by -21 percentage points.

Danaher has an average 1 year price target of $243.09, an upside of 6.4% from Danaher's current stock price of $228.46.

Danaher stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 11 analysts covering Danaher, 54.55% have issued a Strong Buy rating, 27.27% have issued a Buy, 18.18% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.31%, which is 1 percentage points higher than the diagnostic & research industry average of 0.59%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 27.2% indicates that its dividend yield is sustainable for the long-term.

2. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 0.81%, which is the same as the diagnostic & research industry average of 0.59%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 28.1% indicates that its dividend yield is sustainable for the long-term.

3. Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A) has an annual dividend yield of 0.5%, which is the same as the diagnostic & research industry average of 0.59%. Agilent Technologies's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 22.9% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -0.06% in the last day, and down -2.77% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are down.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) is the most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 29, which is 15 points higher than the diagnostic & research industry average of 14. It passed 2 out of 7 valuation due diligence checks.

Qiagen Nv's stock has gained 8.15% in the past year. It has underperformed other stocks in the diagnostic & research industry by -7 percentage points.

2. Fonar (NASDAQ:FONR)

Fonar (NASDAQ:FONR) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Fonar has a valuation score of 71, which is 57 points higher than the diagnostic & research industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has dropped -10.13% in the past year. It has underperformed other stocks in the diagnostic & research industry by -26 percentage points.

3. Revvity (NYSE:RVTY)

Revvity (NYSE:RVTY) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Revvity has a valuation score of 14, which is 0 points higher than the diagnostic & research industry average of 14. It passed 1 out of 7 valuation due diligence checks.

Revvity's stock has dropped -10.22% in the past year. It has underperformed other stocks in the diagnostic & research industry by -26 percentage points.

Are diagnostic & research stocks a good buy now?

57.14% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 3.18% over the next year.

2.08% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 27.08% of diagnostic & research stocks are rated B (Buy), 60.42% are rated C (Hold), 6.25% are rated D (Sell), and 4.17% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 22.79x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.